FORMULATION, DEVELOPMENT AND EVALUATION OF ETHOSOMAL DRUG DELIVERY FOR TERBINAFINE HYDROCHLORIDE

The present research work aimed at the impact of reduced vesicular size on the characteristics of ethosomes by comparing with the regular vesicular size of ethosomes as topical drug delivery vehicle to achieve optimal localized drug concentration and reduced dose frequency of the Terbinafine hydrochloride (TH), an antifungal drug. Oral use of TH contraindicated resulting from sever side effect, thus topical administration is recommended. Commercially available TH creams, lotions and sprays, have limitation of relatively short residual period at target site. The entrapment of drug in vesicles improves localization, solubility and availability of drug at the site; resulting in reduction of the dose. Ethosomal vesicle s were successfully developed through cold method under stirring and sonication and then get in to the ethosomal gel. Sonicated ethosomes were investigated for encapsulation efficiency, UV spectroscopy measurement and % drug content. Photomicroscope investigation not only revealed, vital evidence for presence of phospholipid vesicles in TH ethosomal systems but also displayed greater uniformity in size and shape of sonicated ethosomes. Furthermore, the Comparative investigation wa s carried out for ex vivo skin permeation, ex vivo drug release and entrapment effici ency studies. The present study demonstrates that the ethosoamal vesicle increased the skin penetration of terbinafine both In vitro and in vivo, and did not cause skin irritation. The topical penetration of terbinafine Ethosome was enhanced significantly at 1.5-fold compared to terbinafine marketed cream (Terbicip Cream).